The long war on breast cancer

Overview

The U.S. breast cancer death rate has fallen 44% since its 1989 peak—an estimated 546,000 lives saved. Susan G. Komen's 2026 Progress Outlook attributes three-quarters of this decline to treatment advances and the remainder to earlier detection through mammography screening.

The progress reflects nearly five decades of compounding breakthroughs: tamoxifen in 1978, Herceptin in 1998, and more recently antibody-drug conjugates that deliver chemotherapy directly to cancer cells. Three emerging technologies—oral estrogen receptor degraders, liquid biopsies to detect cancer DNA in blood, and next-generation targeted therapies—promise to extend the gains. Yet the work is unfinished: incidence keeps rising, racial disparities persist, and metastatic disease remains largely incurable.

Play on this story Voices Debate Predict

Key Indicators

44%

Death rate decline since 1989

Breast cancer mortality fell from 33 deaths per 100,000 women at its 1989 peak to approximately 19 per 100,000 in 2023.

546,000

Estimated deaths averted

Lives saved since 1989 due to improved treatment and earlier detection.

FDA-approved drugs linked to Komen research

Over 30 years, Komen-funded research contributed to 30 lifesaving breast cancer treatments.

99%

5-year survival for localized cancer

When caught early and confined to the breast, the five-year relative survival rate is near-perfect.

38%

Higher mortality for Black women

Despite lower incidence, Black women die from breast cancer at rates 38% higher than white women.

Interactive

Exploring all sides of a story is often best achieved with Play.

Ever wondered what historical figures would say about today's headlines?

People Involved

Victoria Wolodzko Smart

Leading Komen's global research and patient support programs

Dennis Slamon

Director, UCLA Clinical/Translational Research

Organizations Involved

Susan G. Komen

Nonprofit organization

World's largest breast cancer nonprofit

Susan G. Komen is the world's largest nonprofit funder of breast cancer research outside the federal government.

U.S. Food and Drug Administration

Federal regulatory agency

Approving new breast cancer treatments at accelerated pace

The FDA regulates drug approvals for cancer treatments in the United States.

Timeline

Komen Reports 44% Decline in Breast Cancer Deaths
Statistics

Susan G. Komen's 2026 Breast Cancer Progress Outlook reported U.S. breast cancer mortality has fallen 44% since 1989, averting an estimated 546,000 deaths. Treatment advances account for 75% of the improvement.
February 3rd, 2026
Giredestrant Shows Promise in Early Breast Cancer
Research

Roche announced its oral SERD giredestrant reduced risk of invasive disease recurrence or death by 30% in early-stage breast cancer—the first oral SERD to show benefit in the adjuvant setting.
December 10th, 2025
Imlunestrant Approved for ESR1-Mutated Cancers
Regulatory

The FDA approved imlunestrant (Inluriyo) for patients with ESR1 mutations, which occur in nearly half of patients who develop resistance to hormone therapy. Unlike earlier drugs, it can cross the blood-brain barrier.
September 25th, 2025
First Oral SERD Approved
Regulatory

The FDA approved elacestrant (Orserdu), the first oral selective estrogen receptor degrader, offering patients with hormone receptor-positive breast cancer a pill-based alternative to injections.
January 27th, 2023
Enhertu Expands to HER2-Low Breast Cancer
Regulatory

The FDA approved Enhertu for HER2-low metastatic breast cancer, extending targeted therapy to an estimated 55% of breast cancer patients previously ineligible.
August 5th, 2022
Enhertu Approved
Regulatory

The FDA approved fam-trastuzumab deruxtecan (Enhertu), a next-generation antibody-drug conjugate that would later expand access to HER2-targeted therapy for patients with low HER2 expression.
December 20th, 2019
First Antibody-Drug Conjugate for Breast Cancer
Regulatory

The FDA approved ado-trastuzumab emtansine (Kadcyla), linking a Herceptin antibody to a chemotherapy payload. It was the first ADC approved for any solid tumor.
February 22nd, 2013
Herceptin Approved: Precision Medicine Arrives
Regulatory

The FDA approved trastuzumab (Herceptin), the first monoclonal antibody for solid tumors. It transformed HER2-positive breast cancer from one of the deadliest subtypes to one of the most treatable.
September 25th, 1998
Breast Cancer Death Rate Peaks
Statistics

U.S. breast cancer mortality reached its highest point at approximately 33 deaths per 100,000 women. Death rates would decline steadily from this point forward.
January 1st, 1989
HER2 Gene Cloned
Research

Scientists cloned the HER2 gene, later discovering its overexpression drives aggressive breast tumors. This finding led to the development of Herceptin.
January 1st, 1985
Susan G. Komen Founded
Organization

Nancy Brinker founded the organization in Dallas to honor her sister Susan, who died from breast cancer at 36. It would become the world's largest breast cancer nonprofit.
January 1st, 1982
Tamoxifen Approved: First Targeted Breast Cancer Drug
Regulatory

The FDA approved tamoxifen, the first drug to block estrogen receptors in breast cancer cells. It would later be shown to reduce recurrence risk by 50% in hormone receptor-positive cancers.
January 1st, 1978

Scenarios

Predict which scenario wins. Contrarian picks score more — points lock in when the scenario resolves.

Predictions leaderboard

Liquid Biopsies Enable Earlier Detection, Mortality Drops Further

Blood-based cancer DNA tests (ctDNA) enter routine clinical use, detecting recurrence 8-12 months before imaging. Combined with new treatments, this could push five-year survival rates for metastatic disease above current 30% levels. NeoGenomics plans to launch its Radar ST test for breast cancer in early 2026, and Oxford's TriOx test shows promise for multi-cancer detection.

Discussed by: Nature, Journal of Clinical Oncology, oncology researchers at Oxford and NeoGenomics

Consensus —

Progress Stalls as Disparities Persist

Overall mortality decline slows to 1% annually (from 2-3% in earlier decades) as gains concentrate among insured, white patients. Black women's 38% higher mortality rate remains unchanged. Without addressing insurance gaps and access barriers—which explain 37% of excess mortality risk for Black patients—the racial disparity continues for another decade.

Discussed by: American Cancer Society, New England Journal of Medicine, Breast Cancer Research Foundation

Consensus —

Metastatic Breast Cancer Becomes Chronic, Manageable Disease

Antibody-drug conjugates and oral SERDs extend median survival for metastatic patients beyond current benchmarks of 2-3 years. Sequential targeted therapies allow patients to cycle through multiple effective treatments. Metastatic breast cancer joins HIV in the category of serious conditions that can be managed for decades rather than measured in months.

Discussed by: AstraZeneca, Eli Lilly, oncology journals covering antibody-drug conjugate trials

Consensus —

Rising Incidence Outpaces Treatment Gains

Breast cancer diagnoses continue rising 1% annually due to obesity, delayed childbearing, and aging populations. Global cases projected to reach 3.2 million annually by 2050. Even with falling death rates, absolute numbers of breast cancer deaths increase as more people are diagnosed.

Discussed by: International Agency for Research on Cancer, American Cancer Society, CA: A Cancer Journal for Clinicians

Consensus —

Historical Context

Polio Eradication Campaign (1955-present)

1955 - present

What Happened

Jonas Salk's vaccine, licensed in 1955, triggered a global campaign that reduced polio cases by over 99%—from 350,000 annual cases in 125 countries in 1988 to just 6 cases in 2021. The Americas were certified polio-free in 1994. Only Afghanistan and Pakistan still report endemic transmission.

Outcome

Short Term

Mass vaccination campaigns eliminated polio from the Western Hemisphere within decades.

Long Term

Demonstrated that sustained research investment combined with public health infrastructure could eliminate a deadly disease. Set template for coordinated global disease eradication.

Why It's Relevant Today

Like polio, breast cancer mortality has declined through the combination of prevention (screening) and treatment advances. Both required decades of investment and infrastructure—though cancer's complexity means control rather than eradication remains the goal.

HIV/AIDS Treatment Revolution (1996-present)

1996 - present

What Happened

The introduction of highly active antiretroviral therapy (HAART) in 1996 transformed HIV from a death sentence into a manageable chronic condition. AIDS deaths in the U.S. fell 47% in 1997 alone. Globally, AIDS-related deaths dropped 70% from their 2004 peak of 2.1 million to 630,000 in 2024.

Outcome

Short Term

U.S. AIDS deaths plummeted immediately after HAART became available. Life expectancy for HIV-positive patients increased dramatically.

Long Term

HIV treatment became a model for precision medicine—matching specific drugs to viral resistance patterns. By 2024, 31.6 million people were accessing antiretroviral therapy worldwide.

Why It's Relevant Today

The HIV precedent shapes expectations for metastatic breast cancer. As targeted therapies multiply, oncologists envision a similar transformation—from terminal diagnosis to chronic condition managed through sequential treatments.

Childhood Leukemia Survival Transformation (1960s-present)

1960s - present

What Happened

In the 1960s, childhood acute lymphoblastic leukemia (ALL) was nearly always fatal, with survival rates below 10%. Through systematic clinical trials testing combination chemotherapy, researchers achieved incremental improvements. By 2020, five-year survival exceeded 90%.

Outcome

Short Term

Each clinical trial generation improved survival by a few percentage points, building on prior gains.

Long Term

Childhood ALL became one of oncology's greatest success stories, demonstrating that sustained research investment over decades could transform an incurable cancer into a largely curable one.

Why It's Relevant Today

Breast cancer's 44% mortality decline over 34 years mirrors the ALL trajectory: incremental gains from screening, hormonal therapy, targeted drugs, and immunotherapy compounding over decades. Both show cancer progress happens in years, not months.